

Poster number	Last name	First name	Ref Code	Title
6	Samuelsson	Isak	9305-A-2515	Association between systemic lupus erythematosus and myocardial infarction subtypes – a matched cohort study in Sweden
8	Alharb	Laila	9441-A-2515	The Epidemiology of Primary Antiphospholipid syndrome in Southern Sweden
9	Gunnarsson	Iva	9393-A-2515	Avacopan in a compassionate use program for severe Anti-Neutrophil Cytoplasmic Autoantibody–Associated Vasculitis - Experiences from rheumatology
12	Sundbeck	Boel	9366-A-2515	A distinct pattern of T-cell and B-cell subpopulations predicts response to CTLA-4 Ig treatment in early rheumatoid arthritis;
14	Ekwall	Anna-Karin	9440-A-2515	Plasma levels of interferon-alpha are associated with the presence of radiographic airway abnormalities in early untreated rheumatoid arthritis;
18	Fors	Charlotta	9109-A-2515	Predictors of developing Polymyalgia Rheumatica: a nested case-control study based on a population survey;
21	Sylwander	Charlotte	9406-A-2515	Knowing the Pain, Embracing Pain, and Building Resilience: Patients’ Experiences of a Multimodal Rehabilitation Program for Chronic Pain
23	Landgren	Ellen	9409-A-2515	Fostering a sense of security in early RA care through a very tight control clinic – A qualitative study
24	Andersson	Maria	9330-A-2515	How do empowerment and lifestyle influence fear-avoidance in patients with long-term RA?
26	Brolin	Sara	9046-A-2515	Patient reported outcome measures and the impact of disease activity, disease duration, and organ involvement in vasculitis and lupus
27	Carstensen	Stine	9122-A-2515	Harmonising consensus and reliability studies in musculoskeletal ultrasound
28	Klingberg	Eva	9335-A-2515	The culprits behind Methotrexate-proposed hepatotoxicity are modifiable risk factors
29	Jensen	Kasper Yde	9343-A-2515	Adalimumab biosimilar-to-biosimilar switch in 1,233 Danish patients with inflammatory rheumatic diseases – Real-world evidence from the DANBIO reg
30	Maglio	Cristina	9348-A-2515	Appraising the causal role of body mass index in rheumatic joint disorders: A systematic review and meta-analysis of Mendelian randomization studies
31	Nabi	Hafsah	9353-A-2515	One-year safety outcomes in 2,132 real-world Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111)
32	Nabi	Hafsah	9434-A-2515	The impact of patient history: effectiveness of infliximab biosimilar GP1111 in 1,910 real-world Danish patients with inflammatory arthritis
33	Timsans	Janis	9388-A-2515	Lower large joint replacement rate in hyperuricemic individuals: could uric acid be chondroprotective?
34	Stjärne	Johan	9457-A-2515	A SELF-MANAGEMENT APP IN A TREAT-TO-TARGET GOUT CARE APPROACH: THE REMONIT GOUT FEASIBILITY STUDY
35	Källmark	Hanna	9101-A-2515	Long-term antibody response to Herpes Zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
36	Källmark	Hanna	9102-A-2515	Cellular immunogenicity to Herpes Zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
37	Lundgren	Victoria	9311-A-2515	Understanding MTX response in early arthritis, how insulin and IFN contribute to successful treatment
38	Abild	Signe Marie	9318-A-2515	Building Bridges Project – Enhancing collaboration across healthcare sectors for inflammatory arthritis
39	Waldenlind	Kristin	9341-A-2515	Do pain patterns in RA patients differ between bDMARD subgroups and their different modes of action?
40	Primdahl	Jette	9395-A-2515	Healthcare professionals’ perceptions of work-related challenges and needs for support among people with inflammatory arthritis.
41	Jäppinen	Katriina	9416-A-2515	Time to reassess our joint assessments?
42	Demirdal	Deniz	9301-A-2515	Correlation analysis of longitudinal anti-MDA5 autoantibody levels with disease activity in Caucasian patients with anti-MDA5 positive dermatomyositis
43	Lodin	Karin	9376-A-2515	Fatigue is associated with disease activity in patients with idiopathic inflammatory myopathies
44	Peralta Garcia	Irene	9396-A-2515	Diagnostic delay in idiopathic inflammatory myopathies: association with disease activity
45	Regardt	Malin	9408-A-2515	IMPROVED ACTIVITY PERFORMANCE USING A POWER ENHANCING GLOVE IN PERSONS WITH INCLUSION BODY MYOSITIS (IBM)
46	Skattør	Marianne	9411-A-2515	Exercise as treatment for patients with inclusion body myositis - study protocol and preliminary results
47	Jensen	Kasper Yde	9423-A-2515	Accelerated ageing in myositis
48	Tydén	Helena	9387-A-2515	Risk factors for cardiovascular events are increased in adults with Juvenile Idiopathic Arthritis - results from the south-Swedish Juvenile Idiopathic Arthri
49	Rauer	Ola	9405-A-2515	Ophthalmological complications after 35 years of juvenile idiopathic arthritis - results from the south-Swedish Juvenile Idiopathic Arthritis cohort
50	Heinicke	Fatima	9462-A-2515	Preliminary Results from Comprehensive Single-Cell Analysis Exploring the Cellular Landscape in JIA Joints and Peripheral Blood
51	Myhre Hjelle	Anja	9364-A-2515	Do HMG-CoA reductase inhibitors protect against osteoporotic distal radius fracture? Results from an observational study of 289 patients
52	Kvien	Tore Kristian	9354-A-2515	NSAID use, gastrointestinal complications, and burden of disease in osteoarthritis: Nordic registry study with emphasis on patients below 60 years
53	Wiking	Emelie	9362-A-2515	Early management of symptomatic knee osteoarthritis and support for healthy lifestyle habits: a scoping review
54	Takahashi	Hiroki	9287-A-2515	Prognosis and clinical characteristics of patients with IgG4-related disease who were followed up for over 20 years at a single institution
55	Nagahata	Ken	9123-A-2515	Delayed glucocorticoid initiation reduces ureteral stent removal rate in IgG4-related retroperitoneal fibrosis
56	Fedotchenko	Andrii	9390-A-2515	The marginal transitional zone of the synovial joint: Histochemical approaches for the identification of its components
57	Di Giuseppe	Daniela	9401-A-2515	Register-based data on diet and alcohol consumption: a new way to collect data on lifestyle factors in rheumatology
58	Sagen	Joachim	9413-A-2515	Volunteer led high-intensity interval training in heated water
59	Sagen	Joachim	9424-A-2515	EULAR recommendations for patient participation in rheumatology research
60	Borg	Alexander	9459-A-2515	A qualitative comparison of clinical reasoning training: LLM-powered social robotic versus computer-based virtual patients for undergraduate medical e
61	Olofsson	Tor	9322-A-2515	Can algometry-assessed pain sensitivity measures distinguish fibromyalgia from non-fibromyalgia in axial spondyloarthritis patients? Results from the pc
62	Pettersson	Susanne	9291-A-2515	“I can just update myself” – Patients’ reflections on their own access to electronic health records in psoriasis and psoriatic arthritis specialist care
63	Ahmadzay	Zohra Faizy	9293-A-2515	Association between metabolic comorbidities and retention rates of first-line b/tsDMARD treatment in patients with psoriatic arthritis: European real-w
64	Nielung	Louise	9314-A-2515	Exploring definitions and prevalence of difficult-to-treat psoriatic arthritis in 13,872 patients from five Nordic registries
65	Wallman	Johan K.	9329-A-2515	Elevated risk for specialised psychiatric care due to depression or anxiety, but not for suicide, in a Scandinavian cohort of patients diagnosed with psoria
66	Pettersson	Susanne	9337-A-2515	To capture patients’ perception of psoriasis – a pilot study within the Swedish Rheumatology Quality Register

67	Alenius	Gerd-Marie	9345-A-2515	Do HLA-B27 have any impact on disease severity in patients with psoriatic arthritis?
68	Schiller	Claes	9453-A-2515	Prevalence and Associated Factors of Depression and Anxiety in Patients with Psoriatic Disease in Northern Sweden
69	Dehlin	Mats	8990-A-2515	Local steroid injection in finger joints in RA, who benefits? Results on effect and predictors thereof from an observational questionnaire study
70	Steiger	Simon	9300-A-2515	Can alternative means of phenotyping RA reduce apparent heterogeneity? A study of three RA disease activity classification and how they compare to DA
71	Brink	Mikael	9309-A-2515	Validation of a Genetic Risk Score Combined with Clinical Variables for Predicting Pulmonary Fibrosis in Rheumatoid Arthritis
72	Primdahl	Jette	9313-A-2515	Ultrasound-identified tenosynovitis as predictor of patient-reported flares in rheumatoid arthritis patients with low disease activity: Findings from an ob
73	Abild	Signe Marie	9317-A-2515	On the edge of dependency: The experience of frailty in older adults living with rheumatoid arthritis - a qualitative interview study
74	Saevarsdottir	Saedis	9327-A-2515	In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity
75	Johansson	Linda	9328-A-2515	ACPA Fine-Specificities are associated with the development of Extra-Articular Manifestations in Rheumatoid Arthritis
76	Raffray	Maxime	9333-A-2515	Uncovering the heterogeneity of care trajectories leading to a RA diagnosis: a Swedish ten-year study
77	Raffray	Maxime	9334-A-2515	The journey of patients from primary care practices to a diagnosis of rheumatoid arthritis in rheumatology
78	Raffray	Maxime	9339-A-2515	How well does Rheumatoid Arthritis serostatus assigned in routine clinical practice match actual RA serology
79	Huss	Viking	9357-A-2515	Rheumatoid arthritis, non-TNFi bDMARDs and JAKi - risks of keratinocyte cancer
80	Karlsson	Marie-Louise	9358-A-2515	Patterns and changes in lifestyle habits of patients with rheumatoid arthritis during the first three years post-diagnosis
81	Friberger Pajalic	Katarina	9367-A-2515	The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
82	Sofudóttir	Björk	9368-A-2515	Agreement and reliability of using thoracic ultrasound for detecting interstitial lung disease in rheumatoid arthritis: Secondary analyses based on the AUI
83	Roine	Maiju	9374-A-2515	Genetics of inflammatory marker trajectories in rheumatoid arthritis
84	Bengtsson	Caroline	9385-A-2515	A nurse-led “tight control” and “treat-to-target” strategy in early rheumatoid arthritis is associated with more pronounced improvement in patient-repor
85	Di Giuseppe	Daniela	9402-A-2515	Choice and Effectiveness of Second DMARDs After MTX: Comparing Biological, Targeted, and Conventional Options in European RA Cohorts
86	Di Giuseppe	Daniela	9403-A-2515	Treatment Patterns and Determinants of DMARD Switching in European Rheumatoid Arthritis Cohorts: A Multi-National Analysis
87	Bokarewa	Maria	9422-A-2515	CD5L has protective anti-inflammatory properties changing monocyte population in rheumatoid arthritis
88	Alsing	Peter	9425-A-2515	The association between socioeconomic status and delayed first contact with a general practitioner in rheumatoid arthritis: The impact of disease activi
89	Lie	Benedicte Alexandra	9426-A-2515	Extracellular vesicle profiles is altered in RA patients and MTX changes the EV protein cargo only in patients experiencing treatment response - Results fr
90	Akkoc	Ahmet	9428-A-2515	Sustainable research in personalized medicine – How to empower a Scandinavian collaboration in rheumatology to onboard new collaborators by acco
91	Mangseth	Henrik	9430-A-2515	Defining abnormal lung function in patients with rheumatoid arthritis
92	Akkoc	Ahmet	9433-A-2515	Six-Month Outcomes of Methotrexate treatment in Rheumatoid Arthritis: Robust Prediction from Sequence-to-Sequence Models in DANBIO
93	Hokkanen	Anna-Mari	9436-A-2515	Impact of biological disease modifying anti-rheumatic drug initiation on healthcare utilization and work disability in Rheumatoid Arthritis: An observator
94	Stojanovic	Aleksandra	9442-A-2515	Persistent effect of antirheumatic therapy on hemostatic parameters one year after treatment initiation in patients with early rheumatoid arthritis NORI
95	Wasén	Caroline	9443-A-2515	Reduced hand strength in rheumatoid arthritis is associated with volume reduction in brain regions with motor function
96	Fryxelius	Anna	9446-A-2515	Advancing Rheumatoid Arthritis Research: Key Priorities Identified through the James Lind Alliance Process
97	Tureson	Carl	9447-A-2515	Significant decline in anti-collagen type II levels over the first year in early RA is associated with lower disease activity after five years
98	Melokhina	Valeriia	9452-A-2515	Achievement of remission by different criteria within six months in patients with early RA: ultrasound inflammation and radiographic progression
99	Chandrasekaran	Venkataragavan	9461-A-2515	Insulin controls the joint-specific T cell phenotype in rheumatoid arthritis: the impact of anti-rheumatic treatment
100	Heinicke	Fatima	9464-A-2515	Zooming in on CD19+ B Cells in DMARD-naïve RA Patients Using Single-Cell Sequencing
101	Jakobsson	Per-Johan	9468-A-2515	Janus kinase inhibitors enhance prostanoid biosynthesis in human whole blood in vitro: implications for cardiovascular side-effects and prevention strat
102	Terslev	Lene	9347-A-2515	Diagnostic value of high-frequency lacrimal gland ultrasound for primary Sjögren’s Disease
103	Björk	Albin	9359-A-2515	What causes Sjögren’s disease? – insights into patients’ thoughts
104	Sari	Fulden	9325-A-2515	What Limits Exercise Capacity? Determinants of Functional Exercise Capacity in Axial Spondyloarthritis
105	Torell	Anna	9332-A-2515	Adherence to a self-managed digitally based intervention with high-intensity interval training for individuals with axial spondyloarthritis
106	Deminger	Anna	9375-A-2515	Predictors of spinal radiographic progression over up to 13 years in patients with radiographic axial spondyloarthritis
107	Hulander	Erik	9389-A-2515	Coronary artery calcification in patients with r-axSpA: a comparative study with matched controls in southwestern Sweden
108	Sagard	Jonas	9391-A-2515	Do axial spondyloarthritis patients with peripheral involvement have more severe disease? Insights from the SPARTAKUS cohort
109	Lobiuc	Andrei	9420-A-2515	Preliminary Findings from a Cross-Sectional Study on Gut Microbiota Alterations in Ankylosing Spondylitis
110	Torell	Anna	9435-A-2515	Physiological and self-reported effects of a digitally based high-intensity interval training intervention among individuals with axial spondyloarthritis – a r
111	Walhelm	Tomas	9074-A-2515	Comorbid psoriasis in Systemic Lupus Erythematosus: A cohort study from a tertiary referral center and the National Patient Register in Sweden
112	Faustini	Francesca	9121-A-2515	Temporal trends and determinants of infection in Lupus nephritis patients with chronic kidney disease
113	Sjöwall	Christopher	9312-A-2515	Increased pentraxin-3 levels in plasma are associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus
114	Sjöwall	Christopher	9363-A-2515	Interferon alpha dependent uPAR expression on monocytes is a candidate source of increased soluble uPAR in patients with SLE at high risk of developing
115	Skoglund	Elisabeth	9373-A-2515	The genetic and epigenetic profile in patients with Systemic Lupus Erythematosus is linked to renal disease and possible to risk for relapse of nephritis
116	Faustini	Francesca	9377-A-2515	Loss of CD72 immune checkpoint molecules on double negative 2 B cells in systemic lupus erythematosus patients: Association with disease activity and
117	Björklund	Niklas	9381-A-2515	Clusters based on disease activity not a predictor for endothelial dysfunction in Systemic Lupus Erythematosus

118	Stockfelt	Marit	9394-A-2515	Maternal vascular malperfusion of the placenta but not chorioamnionitis is associated with small for gestational age infants in systemic lupus erythematosus
119	Winberg	Line	9404-A-2515	Distinct nailfold capillary changes associate with clinical and serological features in patients with systemic lupus erythematosus
120	Jägerback	Sandra	9410-A-2515	Serum levels of soluble urokinase plasminogen activator receptor (suPAR) are associated with lupus nephritis activity and chronicity features in diagnosis of systemic lupus erythematosus
121	Parodis	Ioannis	9412-A-2515	Novel IgG and IgA autoantibodies against DNA- and RNA-binding proteins distinguish systemic lupus erythematosus from health and non-lupus autoimmune diseases
122	Lindblom	Julius	9418-A-2515	Novel IgG and IgA autoantibodies define disease activity and organ manifestations in systemic lupus erythematosus
123	Tomonjic	Nina	9427-A-2515	Altered hemostatic parameters in patients with systemic lupus erythematosus and kidney involvement
124	Grenmyr	Elsa	9432-A-2515	Autoantibodies against Interferon Alpha in Patients with Systemic Lupus Erythematosus
125	Karlsson	Linnea	9437-A-2515	Extraglomerular vascular changes at first renal flare in systemic lupus erythematosus – stronger predictor of long-term renal outcome compared to histopathological findings
126	Linge	Petrus	9439-A-2515	Anti-Glycoprotein V antibodies in Patients with Systemic Lupus Erythematosus correlates with SLEDAI-2K, reduced complement levels and increased risk of thrombotic events
127	Giannakou	Ioanna	9445-A-2515	Increased serum neurofilament light chain levels in systemic lupus erythematosus are associated with circulating Interferon- α , disease activity and patient health-related quality of life
128	Oparina	Nina	9451-A-2515	Integration of independent scRNA-seq datasets kidney biopsies for inflammatory kidney diseases and healthy controls allows to detect cell-cell communication pathways
129	McNicholas	Andrea	9454-A-2515	Prevalence of postpartum hemorrhage in women with systemic lupus erythematosus in relation to antithrombotic treatment – a prospective cohort study
130	Oparina	Nina	9456-A-2515	Bisphenol A Methylation Scores Associate with SLE and Clinical Subphenotypes
131	Överdahl	Cecilia	9379-A-2515	Serum metabolomics profiling in systemic sclerosis
132	Eloranta	Maija-Leena	9431-A-2515	RNA-containing immune complexes induce type I interferons in blood leukocytes from patients with systemic sclerosis
133	Lillpers	Kerstin	9455-A-2515	Evaluation of common and novel risk factors for low bone mineral density in systemic sclerosis, a case control study of 211 patients
134	Gunnarsson	Karin	9460-A-2515	Hematological malignancies in systemic sclerosis – a nationwide population-based register study
135	Tureson	Carl	9331-A-2515	Quantified Intakes of Key Diet Components and the Risk of Developing Giant Cell Arteritis; a Nested Case-Control Study
136	Skaug	Hans Kristian	9400-A-2515	Health-related quality of life in patients with Giant Cell Arteritis: A study based on the Norwegian Vasculitis Registry
137	Sturluson	Ólafur Orri	9365-A-2515	Clinical characteristics of patients with rare head-and-neck organ involvement in ANCA-associated vasculitides
138	Juto	Anna	9392-A-2515	Complement split products on Myeloperoxidase (MPO) positive extracellular vesicles (EVs) in Anti-Neutrophil Cytoplasmic Antibody (ANCA) -associated vasculitis
139	Dahlqvist	Johanna	9399-A-2515	Plasma proteome profiling unravels divergent pathogenic processes associated with PR3-ANCA positive and MPO-ANCA positive vasculitis
140	Brolin	Sara	9407-A-2515	Mood and health-related quality of life over six months treatment with Avacopan.
141	Granath	Annika	9415-A-2515	Disease impact on health-related quality of life, anxiety, and depression, in antineutrophil cytoplasmic antibody-associated vasculitis: A cluster analysis
142	Damgaard	Astrid Jensen	9380-A-2515	Non-pharmacological interventions in adults with mixed connective tissue disease: a systematic literature review
143	Damgaard	Astrid Jensen	9384-A-2515	Training for Health Professionals in Rheumatology to deliver a COMbined Fatigue Intervention (COMFI)
144	Damgaard	Astrid Jensen	9382-A-2515	The Development of a COMbined Fatigue Intervention (COMFI) for People with Inflammatory Arthritis
145	Damgaard	Astrid Jensen	9386-A-2515	Validity and Reliability of the Swedish Versions of the Bristol Rheumatoid Arthritis Fatigue Questionnaires (BRAFs) in Patients with Spondyloarthritis
146	Bogason	Alex	9326-A-2515	Characterization of patients with rheumatoid arthritis based on distinct patterns of pain improvement following treatment with filgotinib: A post hoc analysis
147	Medical	Costello	9352-A-2515	Bimekizumab demonstrated long-term safety and efficacy in patients with psoriatic arthritis and prior inadequate response to TNFi: Final 3-year results
148	Medical	Costello	9355-A-2515	Low uveitis rates in patients with axial spondyloarthritis or psoriatic arthritis treated with bimekizumab: Long-term results from phase 2b/3 trials
149	Ingman	Pontus	9586-A-2515	Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial